Just as several large pharmaceutical companies faced patent cliffs several years ago, the next six years, another wave of original research drugs face patent limits. A recent EvaluatePharma report stated that between 2018 and 2024, sales of medicines that are about to lose patent protection amounted to US$250 billion. The… Continue Reading A new wave of patent cliffs arrives, affecting 250 billion US dollars of original research varieties